GSK (LSE:GSK) has quietly kept shareholders happy this year, with the stock climbing about 34% year to date and roughly 42% ...

GSK stock trades for 13 times earnings and barely 11 times free cash flow. The pharmaceutical giant pays a 3.3% dividend ...

GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term ...

GlaxoSmithKline’s overall stock score is driven by strong financial performance and favorable valuation metrics. The company’s strategic initiatives, including share buybacks and R&D investments, ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK plc announced the grant of options over Ordinary Shares as part of its Share Save ...

On October 31,‍ JPMorgan low‍ered its price target on GSK plc (NYSE:GSK) to 1,440 GBp fro⁠m 1,550 GBp w⁠hile maintaining an Under‌weight rating on the‍ stock, according to a report by The Fly. ‍GSK ...

The average one-year price target for GSK (OTCPK:GLAXF) has been revised to $23.15 / share. This is an increase of 11.52% from the prior estimate of $20.76 dated November 9, 2025. The price target is ...

Investing.com -- Bank of America (BofA) has turned more constructive on two of Europe’s largest drugmakers, upgrading Novartis to Buy and GSK to Neutral as both companies approach a heavy year of ...